Overview
- An analysis of massive electronic health records, including Epic Cosmos, found a roughly 1.24-fold higher lung cancer incidence in patients previously hospitalized with COVID-19.
- In mouse models, severe viral pneumonia sped tumor growth and increased mortality once oncogenic drivers were present, indicating infection acts as a promoter rather than a mutational cause.
- Researchers identified a lasting epigenetic imprint in lung cells that boosted tumor‑associated neutrophils and dampened cytotoxic CD8 T cell function, creating a pro‑tumor microenvironment.
- Prior vaccination prevented the cancer‑promoting reprogramming in animal models, and people with mild COVID did not show the increased risk, with a slight decrease reported instead.
- The team urges enhanced surveillance after severe COVID, flu, or pneumonia—potentially including screening CT scans for high‑risk patients—and notes preclinical benefits from CXCR2 inhibition combined with PD‑L1 blockade.